Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Efficacy and Safety of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration

NCT04107740 is registered in ClinicalTrials.gov with HLB Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04107740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04107740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Efficacy and Safety of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration
Lead sponsor
HLB Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
March 4, 2019
Completion date
February 8, 2021
Enrollment
160 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

spinocerebellar degeneration